This invention relates to the preparation of powders, particularly for the administration of pharmaceuticals to humans.
Pharmaceuticals are often unstable compounds that degrade rapidly during processes that lead to a powder form of the pharmaceutical. Since the pharmaceutical compound is usually carried in an aqueous solution, and the aqueous solution must be dried to form the powder, the required desiccation or drying process may easily damage the pharmaceutical. At the same time, if the process of forming the powder takes too long, or is too energy consuming, the process may become uneconomic.
Freeze drying (lyophilization), which has conventionally been used to prepare pharmaceutical powders, provides a two step preservation and dehydration process in which the product is first frozen and the water is then removed as vapor from the frozen state. As the water passes from the solid phase directly into the vapor phase, it is necessary that the vapor pressure and the temperature of the sublimation zone is held below those of the triple point on the phase diagram for water. The temperature (<<0° C.) and the maintenance of the frozen state lead to very low driving forces for heat and mass transfer and therefore, often to very low drying rates and very long drying times. Thus, despite its capability of providing a very high-quality dehydrated product, freeze-drying has been and remains highly energy-intensive and consequently, is a very expensive dehydration process.
Freeze drying conventionally is carried out in a vacuum, but may also be carried out at or near atmospheric pressure. Atmospheric freeze-drying has been shown to have the added advantage of increasing transfer coefficients and improving the uniformity of the product during lyophilization. For example, Meryman, H. T., Sublimation freeze-drying without vacuum. Science, 130 (1959) 628-629 proposed an atmospheric freeze-drying process in which the partial pressure of water in the drying chamber is held at very low value and he suggested that such a process should be based on the principle of convective freeze drying, i.e. a cold air steam, kept dry by a molecular sieve desiccant or by a refrigerated condenser, should be circulated. More recently, Leuenberger, H., Spray freeze-drying—the process of choice for low water soluble drugs, Journal of Nanoparticle Research, 4:111-119, 2002 has also identified that spray freeze drying helps preserve pharmacological activity of drugs by stabilization in an appropriate matrix.
Despite the potential advantages of atmospheric lyophilization, the challenge still remains to provide a combination of spray-freezing solution/suspension into liquid and atmospheric freeze-drying that meets industrial demands for a pharmaceutical powder process that maintains drug bioactivity at low economic cost.
It is therefore an object of this invention to provide atmospheric spray freeze drying of liquid carrying pharmaceuticals to produce a powder by a pharmaceutical powder process that maintains drug bioactivity at low economic cost. The invention provides a method of manufacturing a powder or particulate pharmaceutical substance, and an apparatus for carrying out the method. The powder produced by this process is believed to exhibit higher emitted dose and better preservation of bioactivity than spray-dried particles and milled particles. In addition, the porous nature of the particles provides rapid dissolution properties. The invention is applicable to the formation of other powders, including powder forms of nutraceuticals and foods.
Therefore, according to an aspect of the invention, there is provided a method of creating a powder, comprising spraying a carrier liquid containing a powder forming ingredient to form a flow of liquid droplets; entraining the flow with a coolant for sufficient time to freeze the liquid droplets into frozen particles; and drying the frozen particles to form a dry powder.
According to a further aspect of the invention, there is provided apparatus for atmospheric spray freeze drying of an ingredient carrying liquid to form a powder, the apparatus comprising: a chamber having an atomizer at one end of the chamber, the atomizer being connected to a source of the ingredient carrier liquid to produce a flow of liquid droplets; a nozzle system for providing a flow of coolant that entrains atomized fluid sprayed by the atomizer; a source of coolant for the nozzle system; and a collector spaced from the atomizer sufficiently that liquid droplets atomized by the atomizer are frozen by the flow of coolant before contact with the collector.
The powder forming ingredient may be suspended or dissolved in the carrier liquid. The entraining flow may be a concurrent flow of coolant, for example as sprayed from a ring nozzle or through porous side walls of a confining chamber. Frozen particles are preferably collected on a filter at an exit from the confining chamber, and drying mostly takes place on the filter. For enhanced drying, the flow over the filter should be at a warmer temperature than for freezing. More than one powder forming ingredient may be present in the carrier liquid.
Other aspects of the invention appear in the claims.
There will now be described preferred embodiments of the invention with reference to the figures, by way of example, and without intending to limit the scope of the invention to the precise examples disclosed here, and in which figures:
The word “comprising” in the claims is used in its inclusive sense and does not exclude other elements being present. The use of the indefinite article “a” in a claim before an element does not exclude more than one of the element being present.
The present invention is widely applicable for producing particulate material and can be used for spray-freeze drying any material amenable to dissolution or suspension in a suitable carrier liquid, such as water. The term powder forming ingredient is used to refer to one or more pharmaceutical, nutraceutical, food or other substances that have utility in powder form. The present invention is especially useful for heat-sensitive substances, such as proteins, nucleic acids, oligonucleotides, enzymes, liposomes, lipids, lipid complexes, anti-virals and vaccines (e.g. involving nonvirulent or attenuated pathogens), carbohydrates, polymers, polysaccharides, and peptides. However, its use is not limited to only large molecules, since the method always produces a powder from any material dissolved or suitably suspended in water; it may be used to create, for example, powder anti-infectives, anti-microbials, anti-inflammatories, antineoplastics, analgesics, anaesthetics, cholinergics, adrenergics, anticonvulsants, anti-depressants, sedatives, tranquilizers and antiemetics, immunosuppressives and immunostimulants, antihistamines, hormones, antivenoms and antitoxins. Cryoprotectants may be added to aid in preventing degradation of substances during processing. The ingredient carrying liquid may contain several different drugs and also excipient material. For example, the particles may be made mostly out of lactose with only a little drug in them. Or there may be several drugs in the ingredient carrying liquid, plus lactose or other filler/matrix/excipient compound.
In the embodiments shown in
Referring to the first embodiment shown in
Referring to a second embodiment shown in
Referring to a third embodiment shown in
The coolant source 120, 220 or 320 may be any source of a coolant that does not contaminate or degrade the powder. Cold gas may be used such as refrigerated nitrogen, particularly for the embodiment shown in
During manufacture, pharmaceutical agents (PA) or other powder forming ingredients are mixed with a carrier liquid prior to spraying from the atomizer 102, 202, 302. The spray fluid resulting from the mixture of PA and carrier liquid may be, for example, a solution, a suspension or a colloid. The atomizer 102, 202, 302 may be a two-fluid nozzle or an ultrasonic nebulizer or a vibrating orifice aerosol generator (VOAG) or other atomizing device. The spray fluid, which is formed of liquid droplets, is rapidly frozen through contact with coolant, which is a cold fluid of a suitable temperature. In the spray-freeze step, cooling fluid may be supplied in several possible ways. One way, shown in
In the example of
After the accomplishment of spray-freezing, a proper drying temperature will be chosen in a drying step by flow rate adjustment from the cooling cryogenic or refrigeration system. In the meantime, the initial frozen powder collected on the exit filter 122, 222, 322 at exit end (bottom) of the chamber will be dried by sublimation in a cold desiccated airstream at atmospheric pressure. Because all the frozen powder falls down or is conveyed by the down stream flow to the exit filter, no matter whether it is cohesive powder or free flow powder, no external forces are needed to re-lift the powder adhering on the walls, unlike in the spray-freeze drying process of a traditional up-stream fluidized bed, which are used in other processes like U.S. Pat. No. 4,608,764.
In addition, less contamination is realized through this invention by screening frozen powder from contacting the sidewalls of the chamber 110, 210, 310 compared to the former technology. As the sublimation process is taking place, the frozen particles become lighter and the aerodynamic behavior changes. The partially dried particles may form a loose cake on the exit filter 122, 222, 322, from which the remaining moisture is removed by atmospheric sublimation using a cold desiccated gas stream, resulting in final free-flowing powders. After spray-freeze atmospheric drying, dry porous particles of roughly the same size and shape as the original frozen droplets are obtained.
Spray freeze atmospheric dried particles produced by this method can have a morphology desirable for respiratory administration of medicament using respiratory delivery devices such as those disclosed in U.S. patent application US60430085 filed Nov. 27, 2003. The typically porous nature of particles formed from this process is also desirable for rapid dissolution, as seen in the BioAqueous technology from Dow Chemical Company, as well as for other purposes such as those disclosed in e.g. U.S. Pat. No. 6,635,283.
Operating Procedures
The apparatus is allowed to run for approximately 5 to 30 minutes to reach the desired temperature in the chamber 110, 210, 310 either by spraying liquid nitrogen directly into it, or by having the cold fluid from a refrigeration system flow into the chamber 110 through the porous wall. The aqueous solution or suspension of the substances to be dried is then sprayed using the atomizer 102, 202, 302 and frozen simultaneously in situ at a chosen temperature by the surrounding curtain of liquid nitrogen generated from ring nozzle 218, 318 or an equivalent such as cryogenic flow from nozzles 118 through porous sidewalls of chamber 110. The frozen powder is conveyed down to the exit filter 122, 222, 322 by the concurrent downstream flow. After completion of the spray-freezing process, the flow of the cryogenic fluid (at a low temperature of −50° C. to −196° C.) is shut off and switched to a cooling gas at a somewhat higher temperature (−10° C. to −30° C.) from the refrigeration system. Then the frozen powder collected on the exit filter 122, 222, 322, at the bottom is dried continuously by sublimation at atmospheric pressure until the remaining moisture of the frozen powder is removed by the cold desiccated gas stream. After spray-freeze atmospheric drying, a loose cake occurs on the exit filter 122, 222, 322, which is very fragile and easily broken into free flowing, dry porous particles of approximately the same size and shape as the original frozen droplets. In order to reduce moisture condensation on the cold particle surface, the temperature of the desiccant cooling gas will be raised to room temperature gradually before the sample is collected from the chamber 100, 200, 300.
In one example, powder was produced using the method described above. A 15 wt % mannitol solution was spray freeze-dried using the apparatus shown in
Mannitol has been spray-frozen by us at −50° C. to −70° C. and dried in a temperature of −5° C. to −20° C. in order to avoid mannitol crystallization (mannitol hydrate occurs at around 38° C.). Based on practical demand (each bio-substance may have its ideal spray-freeze and drying temperature), the spray-freeze drying conditions are adjustable by changing the temperature and flow rate of the mixed cold gases. Depending on the batch scale, these parameters may be different.
For atmospheric pressure freeze drying with dry air, the temperature at which material may be truly freeze dried is set by its melting point. Since the vapor pressure of ice is essentially fixed by the melting point temperature, the rate of freeze-drying is essentially controlled by the resistance to water vapor diffusion in the material. This resistance is proportional to the diffusion path length and the permeability of the material. Atmospheric pressure freeze-drying should therefore be feasible in a wide variety of materials where diffusion distances are very short in materials of open structure.
Immaterial modifications may be made to the invention described here without departing from the invention.
Number | Date | Country | Kind |
---|---|---|---|
2450779 | Dec 2003 | CA | national |
This application is a continuation of U.S. patent application Ser. No. 11/318,864 filed Dec. 28, 2005 now U.S. Pat. No. 7,363,726. U.S. patent application Ser. No. 11/318,864 is a continuation of U.S. patent application Ser. No. 10/762,300 filed Jan. 23, 2004, now U.S. Pat. No. 7,007,406.
Number | Name | Date | Kind |
---|---|---|---|
2460546 | Stephanoff | Feb 1949 | A |
2856278 | Bray et al. | Oct 1958 | A |
3172546 | Schreiner | Mar 1965 | A |
3247014 | Goldberger et al. | Apr 1966 | A |
3252776 | Strickland et al. | May 1966 | A |
3257815 | Brocoff et al. | Jun 1966 | A |
3309777 | Hutton | Mar 1967 | A |
3313032 | Malecki | Apr 1967 | A |
3319344 | Sachsel et al. | May 1967 | A |
3490355 | Groth et al. | Jan 1970 | A |
3565039 | Remer | Feb 1971 | A |
3677405 | Keith, Jr. | Jul 1972 | A |
3749378 | Rhodes | Jul 1973 | A |
3788095 | Murphy et al. | Jan 1974 | A |
3793003 | Othmer | Feb 1974 | A |
3819336 | Rogers et al. | Jun 1974 | A |
3848068 | Rice | Nov 1974 | A |
3853541 | Othmer | Dec 1974 | A |
3938988 | Othmer | Feb 1976 | A |
4015749 | Arzberger et al. | Apr 1977 | A |
4033048 | Van Ike | Jul 1977 | A |
4094808 | Stewart et al. | Jun 1978 | A |
4161084 | Arny et al. | Jul 1979 | A |
4273790 | Bosco et al. | Jun 1981 | A |
4273795 | Bosco et al. | Jun 1981 | A |
4276381 | Sakimae et al. | Jun 1981 | A |
4324707 | Hungerford | Apr 1982 | A |
4389794 | Bitterly | Jun 1983 | A |
4393817 | Lindberg | Jul 1983 | A |
4409253 | Morrison et al. | Oct 1983 | A |
4409931 | Lindberg | Oct 1983 | A |
4455135 | Bitterly | Jun 1984 | A |
4533572 | Neelameggham et al. | Aug 1985 | A |
4541367 | Lindberg | Sep 1985 | A |
4541867 | Neelameggham et al. | Sep 1985 | A |
4608764 | Leuenberger | Sep 1986 | A |
4652434 | Bonsack et al. | Mar 1987 | A |
4768446 | Wilkes et al. | Sep 1988 | A |
4775000 | Ayers | Oct 1988 | A |
4802286 | Kobayashi et al. | Feb 1989 | A |
4820627 | McGeehan | Apr 1989 | A |
4836982 | Brupbacher et al. | Jun 1989 | A |
4837005 | Brode et al. | Jun 1989 | A |
4851722 | Zauderer | Jul 1989 | A |
4873293 | Brode et al. | Oct 1989 | A |
4915905 | Kampe et al. | Apr 1990 | A |
5009994 | McGeehan | Apr 1991 | A |
5015534 | Kampe et al. | May 1991 | A |
5019311 | Koslow | May 1991 | A |
5090132 | Kobayashi et al. | Feb 1992 | A |
5124162 | Boskovic et al. | Jun 1992 | A |
5147722 | Koslow | Sep 1992 | A |
5208998 | Oyler, Jr. | May 1993 | A |
5230162 | Oyler, Jr. | Jul 1993 | A |
5230915 | Shahidi et al. | Jul 1993 | A |
5240656 | Scheeres | Aug 1993 | A |
5269077 | Bruttini | Dec 1993 | A |
5348566 | Sawyer et al. | Sep 1994 | A |
5387489 | Fuller et al. | Feb 1995 | A |
5402992 | Saxena | Apr 1995 | A |
5426003 | Spengler et al. | Jun 1995 | A |
5455057 | Symbolik et al. | Oct 1995 | A |
5468427 | Stangle et al. | Nov 1995 | A |
5518709 | Sutton et al. | May 1996 | A |
5523065 | Stangle et al. | Jun 1996 | A |
5531845 | Flanigan et al. | Jul 1996 | A |
5536893 | Gudmundsson | Jul 1996 | A |
5611973 | Gurfein et al. | Mar 1997 | A |
5612053 | Baichwal et al. | Mar 1997 | A |
5641349 | Koubek et al. | Jun 1997 | A |
5651952 | Grudnoff et al. | Jul 1997 | A |
5651966 | Read et al. | Jul 1997 | A |
5656498 | Iijima et al. | Aug 1997 | A |
5660774 | Stangle et al. | Aug 1997 | A |
5665276 | Kirby et al. | Sep 1997 | A |
5674468 | Klaveness et al. | Oct 1997 | A |
5676925 | Klaveness et al. | Oct 1997 | A |
5727333 | Folan | Mar 1998 | A |
5731540 | Flanigan et al. | Mar 1998 | A |
5738865 | Baichwal et al. | Apr 1998 | A |
5772912 | Lockyer et al. | Jun 1998 | A |
5780055 | Habib et al. | Jul 1998 | A |
5785976 | Westesen et al. | Jul 1998 | A |
5795562 | Klaveness et al. | Aug 1998 | A |
5829255 | Sitnyakovsky et al. | Nov 1998 | A |
5837193 | Childers et al. | Nov 1998 | A |
5843347 | Nguyen et al. | Dec 1998 | A |
5885486 | Westesen et al. | Mar 1999 | A |
5902608 | Read et al. | May 1999 | A |
5928469 | Franks et al. | Jul 1999 | A |
5957848 | Sutton et al. | Sep 1999 | A |
5993804 | Read et al. | Nov 1999 | A |
6015546 | Sutton et al. | Jan 2000 | A |
6022525 | Sutton et al. | Feb 2000 | A |
6050990 | Tankovich et al. | Apr 2000 | A |
6074737 | Jordan et al. | Jun 2000 | A |
6187226 | Detering et al. | Feb 2001 | B1 |
6207178 | Westesen et al. | Mar 2001 | B1 |
6248363 | Patel et al. | Jun 2001 | B1 |
6251193 | Rossy et al. | Jun 2001 | B1 |
6251463 | Rossy et al. | Jun 2001 | B1 |
6261679 | Chen et al. | Jul 2001 | B1 |
6284282 | Maa et al. | Sep 2001 | B1 |
6287550 | Trinh et al. | Sep 2001 | B1 |
6344182 | Sutton et al. | Feb 2002 | B1 |
6348186 | Sutton et al. | Feb 2002 | B1 |
6372258 | Platz et al. | Apr 2002 | B1 |
6387394 | Baichwal et al. | May 2002 | B1 |
6391224 | Wowk | May 2002 | B1 |
6395197 | Detering et al. | May 2002 | B1 |
6413458 | Pearce | Jul 2002 | B1 |
6416741 | Sutton et al. | Jul 2002 | B1 |
6426210 | Franks et al. | Jul 2002 | B1 |
6440336 | Weinreich et al. | Aug 2002 | B1 |
6440463 | Feldstein et al. | Aug 2002 | B1 |
6460376 | Jeanvoine et al. | Oct 2002 | B1 |
6470592 | Akimoto et al. | Oct 2002 | B2 |
6471993 | Shastri et al. | Oct 2002 | B1 |
6509006 | Platz et al. | Jan 2003 | B1 |
6541001 | Gallili et al. | Apr 2003 | B1 |
6565927 | Drzal et al. | May 2003 | B1 |
6569405 | Sutton et al. | May 2003 | B1 |
6569463 | Patel et al. | May 2003 | B2 |
6572910 | Lanner et al. | Jun 2003 | B2 |
6582728 | Platz et al. | Jun 2003 | B1 |
6592869 | Gallili et al. | Jul 2003 | B2 |
6603054 | Chen et al. | Aug 2003 | B2 |
6616858 | Fahy et al. | Sep 2003 | B2 |
6630121 | Sievers et al. | Oct 2003 | B1 |
6673335 | Platz et al. | Jan 2004 | B1 |
6695238 | Inoki et al. | Feb 2004 | B2 |
6716629 | Hess et al. | Apr 2004 | B2 |
6739152 | Jeanvoine et al. | May 2004 | B2 |
6749554 | Snow et al. | Jun 2004 | B1 |
6797258 | Platz et al. | Sep 2004 | B2 |
6825031 | Franks et al. | Nov 2004 | B2 |
6830767 | Teras et al. | Dec 2004 | B2 |
6862890 | Williams et al. | Mar 2005 | B2 |
6893645 | Loughman | May 2005 | B1 |
6921527 | Platz et al. | Jul 2005 | B2 |
6923988 | Patel et al. | Aug 2005 | B2 |
6931888 | Shekunov et al. | Aug 2005 | B2 |
6936279 | Guerra-Santos et al. | Aug 2005 | B2 |
6939530 | Sutton et al. | Sep 2005 | B2 |
6941676 | Akimoto et al. | Sep 2005 | B2 |
6973931 | King | Dec 2005 | B1 |
7007406 | Wang et al. | Mar 2006 | B2 |
7022313 | O'Connor et al. | Apr 2006 | B2 |
7028478 | Prentice, III | Apr 2006 | B2 |
7056877 | Caswell et al. | Jun 2006 | B2 |
7060213 | Pearce | Jun 2006 | B2 |
7073349 | Shekunov et al. | Jul 2006 | B2 |
7076822 | Pearce | Jul 2006 | B2 |
7089681 | Herbert et al. | Aug 2006 | B2 |
7091171 | Caswell et al. | Aug 2006 | B2 |
7094451 | Drzal et al. | Aug 2006 | B2 |
7097675 | Detering et al. | Aug 2006 | B2 |
7097827 | Platz et al. | Aug 2006 | B2 |
7109166 | Moreau | Sep 2006 | B1 |
7122176 | Stamets | Oct 2006 | B2 |
7166565 | Caswell et al. | Jan 2007 | B2 |
7172766 | Baichwal et al. | Feb 2007 | B2 |
7179484 | Singh | Feb 2007 | B2 |
7186680 | Caswell et al. | Mar 2007 | B2 |
7192588 | Gallili et al. | Mar 2007 | B2 |
7220365 | Qu et al. | May 2007 | B2 |
7223447 | Brown et al. | May 2007 | B2 |
7229645 | Maa et al. | Jun 2007 | B2 |
7247288 | Kumta et al. | Jul 2007 | B2 |
7278843 | Feldstein et al. | Oct 2007 | B2 |
7288616 | Tamareselvy et al. | Oct 2007 | B2 |
7326691 | Duddu et al. | Feb 2008 | B2 |
7342079 | Sher et al. | Mar 2008 | B2 |
7351779 | Iaccino et al. | Apr 2008 | B2 |
7354597 | Johnson et al. | Apr 2008 | B2 |
7363726 | Wang et al. | Apr 2008 | B2 |
7369797 | Yoshida et al. | May 2008 | B2 |
7374779 | Chen et al. | May 2008 | B2 |
7423103 | Stavens et al. | Sep 2008 | B2 |
7446084 | Barthel et al. | Nov 2008 | B2 |
7448379 | Yamashita et al. | Nov 2008 | B2 |
7465468 | Cheney et al. | Dec 2008 | B1 |
7494965 | Caswell et al. | Feb 2009 | B2 |
7497877 | Goedhart et al. | Mar 2009 | B2 |
7513121 | Zurecki et al. | Apr 2009 | B2 |
7513132 | Wright et al. | Apr 2009 | B2 |
7517628 | Hirano et al. | Apr 2009 | B2 |
7534304 | Conrad et al. | May 2009 | B2 |
7534758 | Caswell et al. | May 2009 | B2 |
7544651 | Caswell et al. | Jun 2009 | B2 |
7553440 | Leonard | Jun 2009 | B2 |
7578960 | Forbes Jones et al. | Aug 2009 | B2 |
7624595 | Jeanvoine et al. | Dec 2009 | B2 |
7628999 | Sunkara | Dec 2009 | B2 |
7629331 | Pipkin et al. | Dec 2009 | B2 |
7642533 | Partio et al. | Jan 2010 | B2 |
7645351 | Ohno et al. | Jan 2010 | B2 |
7649047 | Tamareselvy et al. | Jan 2010 | B2 |
7658998 | Brown et al. | Feb 2010 | B2 |
7682766 | Fujimoto et al. | Mar 2010 | B2 |
7731954 | Davis et al. | Jun 2010 | B2 |
7735485 | Yamashita et al. | Jun 2010 | B2 |
7758327 | Leonard | Jul 2010 | B2 |
7767249 | Chinea et al. | Aug 2010 | B2 |
7836606 | Gehrmann et al. | Nov 2010 | B2 |
20010024716 | Chen et al. | Sep 2001 | A1 |
20010041743 | Offenbacher et al. | Nov 2001 | A1 |
20020018837 | Lanner et al. | Feb 2002 | A1 |
20020018838 | Zimmerman et al. | Feb 2002 | A1 |
20020022076 | Lanner et al. | Feb 2002 | A1 |
20020028273 | Teras et al. | Mar 2002 | A1 |
20020034571 | Zimmerman et al. | Mar 2002 | A1 |
20020050072 | Akimoto et al. | May 2002 | A1 |
20020061336 | O'Connor et al. | May 2002 | A1 |
20020063235 | Fahy et al. | May 2002 | A1 |
20020072509 | Stein et al. | Jun 2002 | A1 |
20020090345 | Baichwal et al. | Jul 2002 | A1 |
20020094533 | Hess et al. | Jul 2002 | A1 |
20020117170 | Platz et al. | Aug 2002 | A1 |
20020120228 | Maa et al. | Aug 2002 | A1 |
20020127188 | Platz et al. | Sep 2002 | A1 |
20020146394 | Stamets | Oct 2002 | A1 |
20020151604 | Detering et al. | Oct 2002 | A1 |
20020187182 | Kramer et al. | Dec 2002 | A1 |
20020189127 | Akimoto et al. | Dec 2002 | A1 |
20020193290 | Feldstein et al. | Dec 2002 | A1 |
20030006326 | Inoki et al. | Jan 2003 | A1 |
20030026813 | Gallili et al. | Feb 2003 | A1 |
20030029197 | Jeanvoine et al. | Feb 2003 | A1 |
20030040462 | Franks et al. | Feb 2003 | A1 |
20030059435 | Gallili et al. | Mar 2003 | A1 |
20030064097 | Patel et al. | Apr 2003 | A1 |
20030066638 | Qu et al. | Apr 2003 | A1 |
20030068279 | Platz et al. | Apr 2003 | A1 |
20030077297 | Chen et al. | Apr 2003 | A1 |
20030086877 | Platz et al. | May 2003 | A1 |
20030096899 | Pearce | May 2003 | A1 |
20030098438 | Haslin | May 2003 | A1 |
20030101995 | Yamashita et al. | Jun 2003 | A1 |
20030104969 | Caswell et al. | Jun 2003 | A1 |
20030116748 | Haslim | Jun 2003 | A1 |
20030124716 | Hess et al. | Jul 2003 | A1 |
20030129141 | Platz et al. | Jul 2003 | A1 |
20030133876 | Sutton et al. | Jul 2003 | A1 |
20030180352 | Patel et al. | Sep 2003 | A1 |
20030180755 | Hwang et al. | Sep 2003 | A1 |
20030180807 | Hess et al. | Sep 2003 | A1 |
20030185765 | Platz et al. | Oct 2003 | A1 |
20030186271 | Hwang et al. | Oct 2003 | A1 |
20030194506 | Drzal et al. | Oct 2003 | A1 |
20030198601 | Platz et al. | Oct 2003 | A1 |
20030202978 | Maa et al. | Oct 2003 | A1 |
20030207988 | Tamareselvy et al. | Nov 2003 | A1 |
20030215496 | Patel et al. | Nov 2003 | A1 |
20030219466 | Kumta et al. | Nov 2003 | A1 |
20030220039 | Chen et al. | Nov 2003 | A1 |
20030232020 | York et al. | Dec 2003 | A1 |
20030232892 | Guerra-Santos et al. | Dec 2003 | A1 |
20040036054 | Haslim | Feb 2004 | A1 |
20040043042 | Johnson et al. | Mar 2004 | A1 |
20040099612 | Herbert et al. | May 2004 | A1 |
20040117919 | Conrad et al. | Jun 2004 | A1 |
20040139555 | Conrad et al. | Jul 2004 | A1 |
20040154317 | Shekunov et al. | Aug 2004 | A1 |
20040162333 | Mezaache et al. | Aug 2004 | A1 |
20040173146 | Figueroa et al. | Sep 2004 | A1 |
20040173147 | Figueroa et al. | Sep 2004 | A1 |
20040175331 | Figueroa et al. | Sep 2004 | A1 |
20040206124 | Jeanvoine et al. | Oct 2004 | A1 |
20040226098 | Pearce | Nov 2004 | A1 |
20040226099 | Pearce | Nov 2004 | A1 |
20040226726 | Holland et al. | Nov 2004 | A1 |
20040229986 | Pearce | Nov 2004 | A1 |
20040241800 | Jue et al. | Dec 2004 | A1 |
20040247660 | Singh | Dec 2004 | A1 |
20040247870 | Brown et al. | Dec 2004 | A1 |
20050017396 | Pearce et al. | Jan 2005 | A1 |
20050026793 | Caswell et al. | Feb 2005 | A1 |
20050089548 | Virgalitto et al. | Apr 2005 | A1 |
20050089576 | Moreau | Apr 2005 | A1 |
20050091755 | Conrad et al. | May 2005 | A1 |
20050091756 | Wright et al. | May 2005 | A1 |
20050092352 | Luckman et al. | May 2005 | A1 |
20050106553 | Franks et al. | May 2005 | A1 |
20050118939 | Duescher | Jun 2005 | A1 |
20050119165 | Jue et al. | Jun 2005 | A1 |
20050126606 | Goedhart et al. | Jun 2005 | A1 |
20050150059 | Luckman et al. | Jul 2005 | A1 |
20050152946 | Hunter et al. | Jul 2005 | A1 |
20050154374 | Hunter et al. | Jul 2005 | A1 |
20050155393 | Wright et al. | Jul 2005 | A1 |
20050158356 | Hunter et al. | Jul 2005 | A1 |
20050160615 | Wang et al. | Jul 2005 | A1 |
20050161845 | Haas | Jul 2005 | A1 |
20050169960 | Hunter et al. | Aug 2005 | A1 |
20050169961 | Hunter et al. | Aug 2005 | A1 |
20050175664 | Hunter et al. | Aug 2005 | A1 |
20050175665 | Hunter et al. | Aug 2005 | A1 |
20050175703 | Hunter et al. | Aug 2005 | A1 |
20050176611 | Caswell et al. | Aug 2005 | A1 |
20050178020 | Shekunov et al. | Aug 2005 | A1 |
20050178395 | Hunter et al. | Aug 2005 | A1 |
20050178396 | Hunter et al. | Aug 2005 | A1 |
20050181005 | Hunter et al. | Aug 2005 | A1 |
20050181009 | Hunter et al. | Aug 2005 | A1 |
20050181010 | Hunter et al. | Aug 2005 | A1 |
20050182463 | Hunter et al. | Aug 2005 | A1 |
20050183731 | Hunter et al. | Aug 2005 | A1 |
20050186239 | Hunter et al. | Aug 2005 | A1 |
20050186244 | Hunter et al. | Aug 2005 | A1 |
20050186245 | Hunter et al. | Aug 2005 | A1 |
20050187140 | Hunter et al. | Aug 2005 | A1 |
20050187188 | Stein et al. | Aug 2005 | A1 |
20050189049 | Ohno et al. | Sep 2005 | A1 |
20050191361 | O'Connor et al. | Sep 2005 | A1 |
20050196421 | Hunter et al. | Sep 2005 | A1 |
20050202990 | Caswell et al. | Sep 2005 | A1 |
20050208095 | Hunter et al. | Sep 2005 | A1 |
20050211029 | Zurecki et al. | Sep 2005 | A1 |
20050214227 | Prestrelski et al. | Sep 2005 | A1 |
20050238586 | Sutton et al. | Oct 2005 | A1 |
20050260273 | Chinea et al. | Nov 2005 | A1 |
20050260274 | Chinea et al. | Nov 2005 | A1 |
20050266021 | Maa et al. | Dec 2005 | A1 |
20050271737 | Chinea et al. | Dec 2005 | A1 |
20060025355 | Duddu et al. | Feb 2006 | A1 |
20060034816 | Davis et al. | Feb 2006 | A1 |
20060034903 | Maa et al. | Feb 2006 | A1 |
20060034937 | Patel | Feb 2006 | A1 |
20060035027 | Brown et al. | Feb 2006 | A1 |
20060053791 | Prentice | Mar 2006 | A1 |
20060057106 | Yamashita et al. | Mar 2006 | A1 |
20060057213 | Larhrib et al. | Mar 2006 | A1 |
20060073105 | Yamashita et al. | Apr 2006 | A1 |
20060123556 | Caswell et al. | Jun 2006 | A1 |
20060123557 | Caswell et al. | Jun 2006 | A1 |
20060130355 | Wang et al. | Jun 2006 | A1 |
20060135921 | Wiercinski et al. | Jun 2006 | A1 |
20060144869 | Chang et al. | Jul 2006 | A1 |
20060147389 | Staniforth et al. | Jul 2006 | A1 |
20060157507 | Chang et al. | Jul 2006 | A1 |
20060159821 | Brisson et al. | Jul 2006 | A1 |
20060191375 | Feldstein et al. | Aug 2006 | A1 |
20060204282 | Yoshida et al. | Sep 2006 | A1 |
20060210622 | Pace et al. | Sep 2006 | A1 |
20060225422 | Prentice | Oct 2006 | A1 |
20060253988 | Pearce | Nov 2006 | A1 |
20060254419 | Leonard | Nov 2006 | A1 |
20060269861 | Hirano et al. | Nov 2006 | A1 |
20060286205 | Fichtali et al. | Dec 2006 | A1 |
20070003492 | Kitahata et al. | Jan 2007 | A1 |
20070019148 | Ueda | Jan 2007 | A1 |
20070042048 | Platz et al. | Feb 2007 | A1 |
20070043030 | Morton et al. | Feb 2007 | A1 |
20070057416 | Kennedy | Mar 2007 | A1 |
20070062332 | Jones et al. | Mar 2007 | A1 |
20070065371 | Yamashita et al. | Mar 2007 | A2 |
20070093440 | Champion et al. | Apr 2007 | A1 |
20070111918 | Caswell et al. | May 2007 | A1 |
20070114298 | O'Keefe | May 2007 | A1 |
20070117939 | Iaccino et al. | May 2007 | A1 |
20070122418 | Platz et al. | May 2007 | A1 |
20070123477 | Malcolmson et al. | May 2007 | A1 |
20070129297 | Cochrane | Jun 2007 | A1 |
20070166368 | Singh | Jul 2007 | A1 |
20070167340 | Barthel et al. | Jul 2007 | A1 |
20070178399 | Kobayashi et al. | Aug 2007 | A1 |
20070190158 | Hwang et al. | Aug 2007 | A1 |
20070197957 | Hunter et al. | Aug 2007 | A1 |
20070202342 | Whiteford et al. | Aug 2007 | A1 |
20070203047 | Pegelow et al. | Aug 2007 | A1 |
20070203209 | Bartolini et al. | Aug 2007 | A1 |
20070208154 | Stavens et al. | Sep 2007 | A1 |
20070219325 | Sher et al. | Sep 2007 | A1 |
20070224128 | Dennis et al. | Sep 2007 | A1 |
20070241306 | Wehner et al. | Oct 2007 | A1 |
20070254233 | Fujimoto et al. | Nov 2007 | A1 |
20070269392 | Sunkara | Nov 2007 | A1 |
20080009432 | Caswell et al. | Jan 2008 | A1 |
20080020127 | Whiteford et al. | Jan 2008 | A1 |
20080021212 | Whiteford et al. | Jan 2008 | A1 |
20080023657 | Melnychuk et al. | Jan 2008 | A1 |
20080026068 | Brown et al. | Jan 2008 | A1 |
20080038356 | Maa et al. | Feb 2008 | A1 |
20080045646 | Tamareselvy et al. | Feb 2008 | A1 |
20080050793 | Durance et al. | Feb 2008 | A1 |
20080060213 | Gehrmann et al. | Mar 2008 | A1 |
20080075777 | Kennedy | Mar 2008 | A1 |
20080091233 | Ellis-Behnke et al. | Apr 2008 | A1 |
20080095820 | Kumta et al. | Apr 2008 | A1 |
20080142166 | Carson et al. | Jun 2008 | A1 |
20080145658 | Richard et al. | Jun 2008 | A1 |
20080155853 | Wang et al. | Jul 2008 | A1 |
20080161233 | Moreau | Jul 2008 | A1 |
20080172047 | Altshuler et al. | Jul 2008 | A1 |
20080179034 | Forbes Jones et al. | Jul 2008 | A1 |
20080183162 | Altshuler et al. | Jul 2008 | A1 |
20080194494 | Martinez et al. | Aug 2008 | A1 |
20080207581 | Whiteford et al. | Aug 2008 | A1 |
20080214988 | Altshuler et al. | Sep 2008 | A1 |
20080223758 | Scheeres | Sep 2008 | A1 |
20080241269 | Velasquez | Oct 2008 | A1 |
20080305271 | Ring et al. | Dec 2008 | A1 |
20080306471 | Altshuler et al. | Dec 2008 | A1 |
20090000758 | Stone et al. | Jan 2009 | A1 |
20090011037 | Pipkin et al. | Jan 2009 | A1 |
20090016964 | Kalechofsky et al. | Jan 2009 | A1 |
20090053318 | Tan et al. | Feb 2009 | A1 |
20090059138 | Matsumoto et al. | Mar 2009 | A1 |
20090062173 | Caswell et al. | Mar 2009 | A1 |
20090069741 | Altshuler et al. | Mar 2009 | A1 |
20090074859 | Patel | Mar 2009 | A1 |
20090095293 | Yamashita et al. | Apr 2009 | A1 |
20090118503 | Sprott et al. | May 2009 | A1 |
20090123540 | Pipkin et al. | May 2009 | A1 |
20090126732 | Yamashita et al. | May 2009 | A1 |
20090131395 | Antonelli et al. | May 2009 | A1 |
20090136737 | Ring et al. | May 2009 | A1 |
20090169500 | Sunkara | Jul 2009 | A1 |
20090190073 | Yoshino et al. | Jul 2009 | A1 |
20090238878 | Singh | Sep 2009 | A1 |
20090263555 | Tapfer et al. | Oct 2009 | A1 |
20090264653 | Bartolini et al. | Oct 2009 | A1 |
20090272228 | Forbes Jones et al. | Nov 2009 | A1 |
20090272269 | Leonard | Nov 2009 | A1 |
20090280534 | Christensen et al. | Nov 2009 | A1 |
20090311406 | Tapfer et al. | Dec 2009 | A1 |
20090312724 | Pipkin et al. | Dec 2009 | A1 |
20090323459 | Windhab et al. | Dec 2009 | A1 |
20100035789 | Caswell et al. | Feb 2010 | A1 |
20100055049 | Kuo et al. | Mar 2010 | A1 |
20100055266 | Windhab et al. | Mar 2010 | A1 |
20100076108 | Miyashita et al. | Mar 2010 | A1 |
20100115708 | Caswell et al. | May 2010 | A1 |
20100168011 | Jennings et al. | Jul 2010 | A1 |
20100173005 | Prestrelski et al. | Jul 2010 | A1 |
20100190722 | Bevec et al. | Jul 2010 | A1 |
20100197708 | Talley et al. | Aug 2010 | A1 |
20100247712 | Rudolph | Sep 2010 | A1 |
20100258118 | Morton | Oct 2010 | A1 |
20100263696 | Leonard | Oct 2010 | A1 |
20100326437 | Zeng | Dec 2010 | A1 |
20110020947 | Bedingham et al. | Jan 2011 | A1 |
Number | Date | Country |
---|---|---|
2004269422 | Mar 2005 | AU |
2375250 | Dec 2000 | CA |
2386206 | Apr 2001 | CA |
4200678 | Jul 1992 | DE |
4113512 | Oct 1992 | DE |
19750679 | May 1999 | DE |
546597 | Jun 1993 | EP |
S53-114783 | Oct 1978 | JP |
55015788 | Feb 1980 | JP |
55102369 | Aug 1980 | JP |
58138347 | Aug 1983 | JP |
60096530 | May 1985 | JP |
63017670 | Jan 1988 | JP |
S63-36817 | Jul 1988 | JP |
03004946 | Jan 1991 | JP |
06062744 | Mar 1994 | JP |
06292705 | Oct 1994 | JP |
H07-080271 | Mar 1995 | JP |
08280807 | Oct 1996 | JP |
11178509 | Jul 1999 | JP |
2001-518391 | Oct 2001 | JP |
2002-058981 | Feb 2002 | JP |
2002338965 | Nov 2002 | JP |
7900086 | Feb 1979 | WO |
WO 8810150 | Dec 1988 | WO |
WO 03043574 | May 2003 | WO |
03072016 | Sep 2003 | WO |
2005021807 | Mar 2005 | WO |
WO 2005061088 | Jul 2005 | WO |
Number | Date | Country | |
---|---|---|---|
20080155853 A1 | Jul 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11318864 | Dec 2005 | US |
Child | 12050654 | US | |
Parent | 10762300 | Jan 2004 | US |
Child | 11318864 | US |